

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Contents lists available at ScienceDirect



International Journal of Infectious Diseases

journal homepage: www.elsevier.com/locate/ijid



Short Communication

COVID-19 and Lassa fever in Nigeria: A deadly alliance?

Salihu Sabiu Musa^{a,b}, Shi Zhao^{c,d}, Zainab Umar Abdullahi^e, Abdulrazaq Garba Habib^f, Daihai He^{a,*}

^a Department of Applied Mathematics, Hong Kong Polytechnic University, Hong Kong, China

^b Department of Mathematics, Kano University of Science and Technology, Wudil, Nigeria

^c JC School of Public Health and Primary Care, Chinese University of Hong Kong, Hong Kong, China

^d Shenzhen Research Institute of Chinese University of Hong Kong, Shenzhen, China

^e Department of Biological Sciences, Federal University Dutsin-Ma, Katsina, Nigeria

^f Department of Medicine, Bayero University, Kano, Nigeria

ARTICLE INFO

Article history: Received 15 December 2021 Revised 27 January 2022 Accepted 27 January 2022

KEYWORDS: COVID-19 Lassa fever Pandemic

ABSTRACT

As the COVID-19 pandemic poses serious threats to global public health, Nigeria faces a potential public health crisis owing to COVID-19 and other infectious diseases, such as Lassa fever (LF) and malaria. In this study, we discuss the possible determinants behind the decreased number of LF cases in Nigeria, which was likely due to the synergistic impact of the COVID-19 pandemic. During the COVID-19 pandemic, the epidemic curve of LF seems to have deviated from the general seasonal scale seen in past years, which could be due to underreporting of cases. In addition, partial compliance with nonpharmaceutical interventions, limited resources, or human behavior could be contributing factors. Thus, we suggest that better differentiation in terms of human and resource allocation between COVID-19 and LF could help curtail the transmission effectively.

© 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

COVID-19 has become one of the most dangerous pandemics to cause severe problems for humanity in the past decades. SARS-CoV-2, a virus that causes COVID-19, emanated from China in December 2019, when public health officials alerted the World Health Organization (WHO) about pneumonia of an unknown etiology (WHO, 2021; Li et al., 2020). Subsequently, the disease rapidly spread worldwide. Nigeria faces a potential public health crisis owing to the synergistic epidemic of COVID-19 and other infectious diseases (Sherrard-Smith et al., 2020; Bouba et al., 2021). A synergistic or syndemic epidemic refers to a concurrent or sequential epidemic causing an excess burden of 2 or more diseases with biological interactions (https://en.wikipedia.org/wiki/Syndemic).

COVID-19 morbidity and mortality rates have rapidly increased in Nigeria since early 2020 (Figure 1a) (NCDC, 2021). Concurrently, the country has witnessed a series of Lassa fever (LF) outbreaks, a deadly zoonotic disease transmitted by rodents (NCDC, 2021). The LF spread has consistently been increasing since 2018 (Figure 1b) (NCDC, 2021). By November 14, 2021, only 418 cumulative LF cases (with 79 fatalities) were recorded nationwide throughout the year; however, there were 1136 cumulative cases and 234 deaths recorded during the same period in 2020 (NCDC, 2021). The time-series analysis for COVID-19 and LF was conducted using the R statistical software (version 4.0.3; The R Foundation for Statistical Computing, Vienna, Austria). The data were obtained from the WHO COVID-19 dashboard and the Nigeria Centre for Disease Control (NCDC) diseases situation report, which is based on laboratory confirmation following the case definition (WHO 2021; NCDC, 2021).

The decrease in LF cases during the pandemic was plausibly owing to the syndemic impact and underreporting issues, as observed in other diseases such as malaria (Sherrard-Smith et al., 2020). In particular, the LF morbidity and mortality cases significantly decreased during the first 3 months of 2021, compared with the same period in previous years. During the LF epidemiological peak period (i.e., roughly the first 15 weeks of each year), we observed an increase in LF cases by +296 from 2017 to 2018, by +86 from 2018 to 2019, and by +451 from 2019 to 2020. However, a notable decrease of -727 was observed from 2020 to 2021 (Figure 2a and b), indicating plausible underreporting of LF in 2021

(S.S.

Musa).

^{*} Corresponding author. E-mail addresses: salihu-sabiu.musa@connect.polyu.hk

zhaoshi.cmsa@gmail.com (S. Zhao), zainabdeedeeumar@gmail.com (Z.U. Abdullahi), abdulrazaq_habib@yahoo.co.uk (A.G. Habib), daihai.he@polyu.edu.hk (D. He).

https://doi.org/10.1016/j.ijid.2022.01.058

^{1201-9712/© 2022} The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)




Figure 1. Time-series plots of COVID-19 and LF in Nigeria. Figure (a) represents the COVID-19 situation reports for 2020 and 2021. Figure (b) represents the LF situation reports for 2018 to 2021. Data were obtained from WHO (2021) and NCDC (2021). COVID-19 = coronavirus disease 2019; LF = Lassa fever; NCDC = Nigeria Centre for Disease Control; WHO = World Health Organization.




Figure 2. Time-series plots of COVID-19 and LF in Nigeria for January-March. Figure (a) represents the COVID-19 situation reports for the first 3 months of 2020 and 2021. Figure (b) represents the LF situation reports for the first 3 months in each of 2018 to 2021. Data were obtained from WHO (2021) and NCDC (2021). COVID-19 = coronavirus disease 2019; LF = Lassa fever; WHO = World Health Organization; NCDC = Nigeria Centre for Disease Control.

owing to COVID-19. In addition, owing to the mild and asymptomatic nature of COVID-19 and LF, which could reach up to 80% (Musa et al., 2020; WHO Africa, 2021), coupled with noncompliance with nonpharmaceutical interventions, the LF cases are likely to be underreported, especially during the pandemic when people are afraid of showing up for tests owing to the fear of COVID-19. Consequently, the LF cases are often observed to rise at the beginning of each year and attain a peak between January and March (Zhao et al., 2020). The peak of the COVID-19 pandemic occurred during the same period in 2021 (Figure 1a) when respiratory diseases are most commonly found. This temporal coincidence might cause even more devastating public health and socioeconomic setbacks, which require intensive public health intervention.

COVID-19 and LF are difficult to distinguish (especially at the early stage) because they share some clinical features (Sherrard-Smith et al., 2020). Furthermore, co-infections with arboviruses have not been well studied in Africa. Amid this complex epidemio-logical scenario, Nigeria's resource-limited health care system faces the risk of being overwhelmed with multiple socioeconomic crises. Limited medical/health care resources (such as intensive care units, real-time reverse transcription polymerase chain reaction) further make it difficult to respond to emergencies or detect virus importation early to prevent onward transmission (Ohia et al., 2020). Another concern lies in the costs of hospitalization owing to LF.

Moreover, the pandemic has significantly affected malaria transmission (Sherrard-Smith et al., 2020) given that malaria also shares many clinical symptoms with COVID-19. Before the outbreak of COVID-19, malaria control had been successful because of the effective allocation of long-lasting insecticidal nets (LLINs) and other control measures. However, it is now challenging to distribute LLINs because of the impact of the pandemic. In addition, the public is afraid of reporting malaria symptoms owing to the fear of COVID-19, which likely increases morbidity and mortality cases (Sherrard-Smith et al., 2020).

COVID-19 by itself has great potential to engulf a health care system, and the situation can worsen when accompanied by an LF outbreak. Nigerian authorities are making every possible effort to suppress/mitigate the pandemic while paying attention to other diseases of public health significance. Previous studies revealed the plausibility of COVID-19 underreporting accelerating disease transmission (Musa et al., 2021; Li et al., 2020). Furthermore, it is imperative to investigate LF cases that are likely underreported during the pandemic.

Although LF has a high mortality rate (especially in pregnancy), early treatment of symptoms by ribavirin and rehydration enhances survival (WHO Africa, 2021). There is currently no licensed vaccine against LF. However, there are a few candidate vaccines in development, which, when ready, are expected to provide protection against LF infection and help prevent neurological complications and deafness caused by LF. Nevertheless, the availability of several COVID-19 vaccines against the infection helps in reducing morbidity and mortality cases. Therefore, substantial improvement in research and medical resources is required for achieving effective disease control. This could help increase the reporting rate and, in turn, suppress COVID-19 and LF outbreaks in Nigeria.

Disclosures

The authors declare that they have no competing interests.

Funding

None.

Acknowledgments

None.

Authors' contributions

All authors contributed equally.

Ethics approval and consent to participate

Ethics approval was not needed because all the data used in this work can be obtained in the public domain.

Consent to publish

Not applicable.

Availability of data and materials

All the data used can be obtained in the public domain.

References

- Bouba Y, Tsinda EK, Fonkou MDM, Mmbando GS, Bragazzi NL, Kong JD. The Determinants of the Low COVID-19 Transmission and Mortality Rates in Africa: A Cross-Country Analysis. Front Public Health 2021;9.
- Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science 2020;368(6490):489–93.
- Musa SS, Zhao S, Gao D, Lin Q, Chowell G, He D. Mechanistic modelling of the large-scale Lassa fever epidemics in Nigeria from 2016 to 2019. J Theor Biol 2020;493.
- Musa SS, Zhao S, Hussaini N, Zhuang Z, Wu Y, Abdulhamid A, et al. Estimation of COVID-19 under-ascertainment in Kano, Nigeria during the early phase of the epidemics. Alex Engr J 2021;60(5):4547–54.
- Nigeria Centre for Disease Control. Diseases Situation Report. 2021. https://ncdc.gov. ng/. Assessed 21 October 2021.
- Ohia C, Bakarey AS, Ahmad T. COVID-19 and Nigeria: putting the realities in context. Int J Infect Dis 2020;95:279–81.
- Sherrard-Smith E, Hogan AB, Hamlet A, Watson OJ, Whittaker C, Winskill P, et al. The potential public health consequences of COVID-19 on malaria in Africa. Nat Med 2020;26(9):1411–16.
- World Health Organization. WHO Coronavirus disease (COVID-19) Dashboard; 2021 https://covid19.who.int/ Assessed 21 October 2021.
- World Health Organization Regional Office for Africa. Lassa fever. 2021. https:// www.afro.who.int/health-topics/lassa-fever. Assessed 20 January 2022.
- Zhao S, Musa SS, Fu H, He D, Qin J. Large-scale Lassa fever outbreaks in Nigeria: quantifying the association between disease reproduction number and local rainfall. Epidem Infect 2020;148:1–12 e4.